GRI Bio announced the authorization of its Clinical Trial Application by the United Kingdom Medicines and Healthcare products Regulatory Agency to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK. The Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study will enroll approximately 36 subjects with IPF whom will be randomized in a 2:1 ratio for GRI-0621 4.5mg or a placebo. GRI-0621 dose of 4.5mg will be compared with a dose of placebo following once daily oral administration for 12 weeks. Concurrently, a sub-study will examine the number and activity of NKT cells in bronchoalveolar lavage fluid for up to 12 eligible subjects. An interim analysis will be performed when 24 subjects complete 6 weeks of treatment. The primary endpoint for the study is safety and tolerability of oral GRI-0621 as assessed by clinical labs, vital signs and adverse events after 12 weeks of treatment. Secondary endpoints are baseline changes in serum biomarkers collected at week 6 and week 12; an assessment of the pharmacokinetics of GRI-0621 at the week 12 visit of treatment; and a determination of the pharmacodynamic activity of oral GRI-0621 as measured by inhibition of iNKT cell activation in blood after 6 weeks and 12 weeks, and from BAL fluid after 12 weeks of treatment in a sub-study. An additional exploratory endpoint for the study is to assess the effect of GRI-0621 on pulmonary function at baseline and after 6 weeks and 12 weeks of treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GRI:
- GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
- GRI Bio Announces Offering Pricing Details
- GRI Bio Launches Major Securities Public Offering
- GRI Bio Announces Pricing of $5.5 Million Public Offering
- GRI Bio prices 5M shares at $1.10 in public offering